The presently disclosed subject matter provides compositions, kits, and methods for administering a prenatal dietary supplement comprising at least about 3 mg of bioavailable, fluoride to a pregnant woman.

The presently disclosed subject matter provides compositions, kits, and methods for administering a prenatal dietary supplement comprising at least about 3 mg of bioavailable, fluoride to a pregnant woman.

The present invention provides nutritional compositions that are employed as oral supplementation to the human diet and methods for using such nutritional compositions. The compositions of the present invention provide for supplementation to the diet of the cancer patient, as well as preventative dietary supplementation aimed at supporting the human immune system for those not currently suffering from cancer. Methods are provided that utilize specific combinations of selected forms selenium. chromium, and molybdenum in combination with fish oil.

The present invention provides nutritional compositions that are employed as oral supplementation to the human diet and methods for using such nutritional compositions. The compositions of the present invention provide for supplementation to the diet of the cancer patient, as well as preventative dietary supplementation aimed at supporting the human immune system for those not currently suffering from cancer. Methods are provided that utilize specific combinations of selected forms selenium. chromium, and molybdenum in combination with fish oil.

The present invention relates to a pharmaceutical composition for preventing or treating COVID-19 diseases, comprising an organic solvent extract of Justicia procumbens as an effective ingredient, a pharmaceutical composition for preventing or treating COVID-19 diseases, comprising justicidin-A as an effective ingredient, a pharmaceutical composition for preventing or treating COVID-19 diseases, comprising justicidin-B as an effective ingredient, or a pharmaceutical composition for preventing or treating COVID-19 diseases, comprising 6′ hydroxyl justicidin-B as an effective ingredient, and a food composition thereof for preventing or ameliorating COVID-19 diseases. According to the present invention, an anhydrous ethanol extract of Justicia procumbens, justicidin-A, justicidin-B, and 6′ hydroxyl justicidin-B effectively inhibit SARS-CoV-2 virus, and thus may effectively prevent, treat, or ameliorate diseases caused by SARS-CoV-2 virus.

The present invention relates to a pharmaceutical composition for preventing or treating COVID-19 diseases, comprising an organic solvent extract of Justicia procumbens as an effective ingredient, a pharmaceutical composition for preventing or treating COVID-19 diseases, comprising justicidin-A as an effective ingredient, a pharmaceutical composition for preventing or treating COVID-19 diseases, comprising justicidin-B as an effective ingredient, or a pharmaceutical composition for preventing or treating COVID-19 diseases, comprising 6′ hydroxyl justicidin-B as an effective ingredient, and a food composition thereof for preventing or ameliorating COVID-19 diseases. According to the present invention, an anhydrous ethanol extract of Justicia procumbens, justicidin-A, justicidin-B, and 6′ hydroxyl justicidin-B effectively inhibit SARS-CoV-2 virus, and thus may effectively prevent, treat, or ameliorate diseases caused by SARS-CoV-2 virus.

Embodiments of the present invention are directed to ingredients, formulations, methods of manufacture and use of an oral rehydration solution (“ORS”) in the prevention and treatment of dehydration in humans. More specifically, invention embodiments relate to flavored electrolyte drink mixtures that relieve the dehydrating effects caused by travel, exercise, over-indulgence of toxic substances, and various illnesses in individual subjects. An ORS embodiment of the present invention restores fluid and electrolyte balance in humans as fast and as effectively as IV therapy, and thereby reduces the incidence of dehydration in human populations as well as rehydrating individuals in circumstances where IV therapy is not practical or wanted. The disclosed ORS therapies and packs may be used in conjunction with IV therapy as a multi-part strategy to allow hospitals to lower patient re-admission rates, lower staffing needs, give outpatient self-therapy to treatments prescribed outside of the hospital environment, and thus lower treatment and process costs while not reducing system or treatment efficacy.

Embodiments of the present invention are directed to ingredients, formulations, methods of manufacture and use of an oral rehydration solution (“ORS”) in the prevention and treatment of dehydration in humans. More specifically, invention embodiments relate to flavored electrolyte drink mixtures that relieve the dehydrating effects caused by travel, exercise, over-indulgence of toxic substances, and various illnesses in individual subjects. An ORS embodiment of the present invention restores fluid and electrolyte balance in humans as fast and as effectively as IV therapy, and thereby reduces the incidence of dehydration in human populations as well as rehydrating individuals in circumstances where IV therapy is not practical or wanted. The disclosed ORS therapies and packs may be used in conjunction with IV therapy as a multi-part strategy to allow hospitals to lower patient re-admission rates, lower staffing needs, give outpatient self-therapy to treatments prescribed outside of the hospital environment, and thus lower treatment and process costs while not reducing system or treatment efficacy.

Embodiments disclosed relate to a nutritional formula having non-fat milk powder, lactose, an oil blend, enriched whey protein concentrate, oligosaccharides, choline, arachidonic acid (ACA), docosahexaenoic acid (DHA), magnesium oxide, sodium citrate, lactoferrin, inositol, taurine, iron, L-carnitine, zinc, nucleotides, soy lecithin, pantothenic acid, copper, D-biotin, folic acid, lutein, manganese sulfate, iodine, Beta-carotene, and selenium, and to methods of delivering nutrition to a subject.

Embodiments disclosed relate to a nutritional formula having non-fat milk powder, lactose, an oil blend, enriched whey protein concentrate, oligosaccharides, choline, arachidonic acid (ACA), docosahexaenoic acid (DHA), magnesium oxide, sodium citrate, lactoferrin, inositol, taurine, iron, L-carnitine, zinc, nucleotides, soy lecithin, pantothenic acid, copper, D-biotin, folic acid, lutein, manganese sulfate, iodine, Beta-carotene, and selenium, and to methods of delivering nutrition to a subject.